Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Combo-Product Review In A Rapidly Changing Environment

Executive Summary

Croma Pharma executive Arkan Zwick talks about the challenges of getting the drug element of a device-type drug/device combination product reviewed in the EU and how companies should proceed in selecting a notified body to review combinations.

You may also be interested in...



Arkan Zwick Q&A, Part 1: Choosing An EU Notified Body For Drug/Device Combinations In A Rapidly Changing Environment

Selecting a notified body that has capacity, expertise and staying power is a challenge in itself. But when it comes to selecting a good one for drug/device combinations products, how should companies proceed? Croma Pharma executive Arkan Zwick offers his insight in this first part of a two-part Q&A. Check out the second part here.

UK Responsible Person, EU ARs and Northern Ireland: The View From MedTech Europe

The UK responsible person is the UK equivalent of the Authorized Representative in the EU. MedTech Europe’s Jesús Rueda gives an update on the early experiences of medtech manufacturers seeking to comply with the UK’s new standalone regulations.

EU Notified Body Association Takes Steps To Allay EC’s Virtual Audit Fears

The European Commission has reluctantly allowed virtual audits in the context of new MDR and IVDR. The EU notified body association is helping the collective effort to meet its strict requirements.

Topics

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel